Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Zoran Andric"'
Autor:
Li Zhang, Goetz Kloecker, Christian Rolfo, Wallace Akerley, Miklos Pless, Lubos Petruzelka, Zoran Andric, Joachim Aerts, Libor Havel, Jeffrey Ward, Richard Greil, David E Gerber, Janusz Milanowski, Angelo Delmonte, Sujith Kalmadi, Rodryg Ramlau, Rupesh Kotecha, Corey Langer, Ticiana A Leal, Manuel Cobo Dols, Jaromír Roubec, Thierry Berghmans, Rajiv Panikkar, Michael Eaton, Mussawar Iqbal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d606e4f0232746d8b3133a817cfbb80c
Autor:
Zoran Andric, MD, Gabriella Gálffy, MD, Manuel Cobo Dols, MD, Barna Szima, MD, Goran Stojanovic, MD, Marina Petrovic, MD, Enriqueta Felip, MD, David Vicente Baz, MD, Santiago Ponce Aix, MD, Oscar Juan-Vidal, MD, Zsuzsanna Szalai, MD, Gyorgy Losonczy, MD, Antonio Calles Blanco, MD, Reyes Bernabe, MD, Gema García Ledo, MD, Andrés Aguilar Hernández, MD, Klaus Duecker, PhD, Dongli Zhou, PhD, Andreas Schroeder, MD, Guelseren Guezel, MD, Fortunato Ciardiello, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100461- (2023)
Introduction: We present the results of a phase 2a trial of first-line avelumab (anti–programmed death-ligand 1 antibody) plus cetuximab (anti–EGFR antibody) in patients with advanced squamous NSCLC. Methods: Patients with recurrent or metastatic
Externí odkaz:
https://doaj.org/article/283d0b24db6b460b8d6628f029ba7cc0
Autor:
Claire Verschraegen, Zoran Andric, Fedor Moiseenko, Tamta Makharadze, Sergii Shevnya, Alona Oleksiienko, Eduardo Yañez Ruiz, SungHyun Kim, KeumYoung Ahn, TaeHong Park, Sijin Park, Hana Ju, Yuichiro Ohe
Publikováno v:
BioDrugs. 36:749-760
CT-P16 is a candidate bevacizumab biosimilar.This double-blind, multicenter, parallel-group, phase III study aimed to establish equivalent efficacy between CT-P16 and European Union-approved reference bevacizumab (EU-bevacizumab) in patients with met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1de1ffc67017e38145496d6e2adc2a00
https://doi.org/10.1007/s40259-022-00552-8
https://doi.org/10.1007/s40259-022-00552-8
Autor:
Ivan Nikolic, Nebojsa Manojlovic, Zoran Andric, Davorin Radosavljevic, Marija Ristic, Vladimir Kovcin
Publikováno v:
Medical review. 75:12-18
Introduction. Patients with colorectal cancer with metastases in the liver parenchyma may benefit from perioperative chemotherapy with biological agents and operative liver resection. Material and Methods. This prospective, multicenter, non-intervent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d3c381dbb713e35aac199a4c7fc9589
https://doi.org/10.2298/mpns2202012n
https://doi.org/10.2298/mpns2202012n
Autor:
Zoran Andric, Gabriella Gálffy, Manuel Cobo Dols, Barna Szima, Goran Stojanovic, Marina Petrovic, Enriqueta Felip, David Vicente Baz, Santiago Ponce Aix, Oscar Juan-Vidal, Zsuzsanna Szalai, Gyorgy Losonczy, Antonio Calles Blanco, Reyes Bernabe, Gema García Ledo, Andrés Aguilar Hernández, Klaus Duecker, Dongli Zhou, Andreas Schroeder, Guelseren Guezel, Fortunato Ciardiello
Publikováno v:
Scientia
Avelumab; Cetuximab; Non–small cell lung cancer Avelumab; Cetuximab; Càncer de pulmó de cèl·lules no petites Avelumab; Cetuximab; Cáncer de pulmón de células no pequeñas Introduction We present the results of a phase 2a trial of first-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb98f97658e063447935929e1c8745e
https://hdl.handle.net/11351/9109
https://hdl.handle.net/11351/9109
Autor:
Solange Peters, Rafal Dziadziuszko, Alessandro Morabito, Enriqueta Felip, Shirish M. Gadgeel, Parneet Cheema, Manuel Cobo, Zoran Andric, Carlos H. Barrios, Masafumi Yamaguchi, Eric Dansin, Pongwut Danchaivijitr, Melissa Johnson, Silvia Novello, Michael S. Mathisen, Sarah M. Shagan, Erica Schleifman, Jin Wang, Mark Yan, Simonetta Mocci, David Voong, David A. Fabrizio, David S. Shames, Todd Riehl, David R. Gandara, Tony Mok
Publikováno v:
Scientia
Non-small-cell lung cancer; Predictive markers Càncer de pulmó de cèl·lules no petites; Marcadors predictius Cáncer de pulmón de células no pequeñas; Marcadores predictivos Tumor mutational burden (TMB) is being explored as a predictive bioma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::350ee20c9b5fb25ff060121a7b7b6043
https://hdl.handle.net/11351/9339
https://hdl.handle.net/11351/9339
Autor:
Marina Maglakelidze, Dinara E. Ryspayeva, Zoran Andric, Zoran Petrovic, Iurie Bulat, Ivan Nikolic, Rajnish Nagarkar, Ursula Wiedermann, Brent A. Blumenstein, Leslie Mi Ok Chong, Nicholas Ede, Bonnie Nixon, Sharon Yavrom, Giovanni Selvaggi, Anthony J. Good, Tanuj Chawla
Publikováno v:
Journal of Clinical Oncology. 41:289-289
289 Background: Active immunization with the B-lymphocyte stimulating HER2 vaccine, HER-Vaxx (IMU-131), has shown clinical response correlated with HER2-specific antibodies (Wiedermann et. al., Clinical Cancer Research, 2021). The HER-Vaxx HERIZON st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49be2e69dff241ffc157393951469ce3
https://doi.org/10.1200/jco.2023.41.4_suppl.289
https://doi.org/10.1200/jco.2023.41.4_suppl.289
Autor:
Yuichiro Ohe, Igor Bondarenko, Zoran Andric, Yuriy Ostapenko, Tudor Ciuleanu, Fedor Moiseenko, Tamta Makharadze, Sergii Shevnya, Alona Oleksiienko, Eduardo Yañez Ruiz, SungHyun Kim, KeumYoung Ahn, TaeHong Park, Sijin Park, JiEun Lee, MinJi Kim, Claire Verschraegen
Publikováno v:
Cancer Research. 82:CT551-CT551
Background: CT-P16 is a proposed biosimilar to FDA approved reference bevacizumab (BV), namely Avastin®. This trial (NCT03676192) compared the efficacy and safety of CT-P16 and BV in patients with metastatic or recurrent non-squamous NSCLC. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95b5003897202a39a18a3e58669ea4f6
https://doi.org/10.1158/1538-7445.am2022-ct551
https://doi.org/10.1158/1538-7445.am2022-ct551
Autor:
Zoran Andric, Vesna Milicic, Marko Kostic, Sanja Kocic, Zafir Murtezani, Zoran Kozomara, Nebojsa Ivanovic, Sanja Kostić
Publikováno v:
Vojnosanitetski Pregled, Vol 77, Iss 9, Pp 908-916 (2020)
Background/Aim. Breast cancer comprises about 25% of all female cancers, and its incidence is increasing. New diagnostic procedures and therapeutic modalities have increased treatment success rates as well as patient survival. The goal of contemporar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85855b23c036318baafb86c1629ae0d6
https://zenodo.org/record/4725405
https://zenodo.org/record/4725405
Autor:
N. Ede, A. Good, Ursula Wiedermann, D. Ryspayenva, Iurie Bulat, V. Choudhary, Ivan Nikolic, Davorin Radosavljevic, Marina Maglakelidze, Zoran Andric, T. Chawla, L. Chong, G. Venkata, B. Nixon, Rita Laeufle, Zoran Petrovic
Publikováno v:
Annals of Oncology. 32:S154
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8867bf0f5bd75876293ad76290b5f41
https://doi.org/10.1016/j.annonc.2021.05.214
https://doi.org/10.1016/j.annonc.2021.05.214